New Zealand’s Black-Market Peptide Surge: Seizures Triple, Needle Demand Soars, Regulators Warn of Unknown Risks

New Zealand is confronting a sharp rise in black-market peptide use, with border seizures nearly tripling and needle-exchange demand surging since the first weight-loss drugs were approved last year, The Spinoff reported.

Customs officers detained 840 peptide parcels in the nine months to September, up from 370 in all of 2025, while the Needle Exchange Programme distributed 2,300 free injecting kits to pharmacies after diabetic syringes ran short. Medsafe, the medicines regulator, issued a warning in May naming 12 unapproved peptides and selective androgen receptor modulators, including the “Wolverine shot” blend of BPC‑157 and TB‑500 and the tanning agent melanotan II, often called the “Barbie drug.”

Deborah Woodley of Te Whatu Ora Health New Zealand told The Spinoff that providing the kits isn’t an endorsement of unapproved peptide use, noting that peptide clients now make up 40 percent of the exchange’s caseload across the central and upper North Island.

YouTube video nKOIujoZFFY — The Spinoff

Wegovy, the approved GLP‑1 treatment, retails at $370‑$475 a month depending on dose. That price tag has pushed some users toward unregulated alternatives. One person told RNZ they spent $200 on retatrutide, a peptide still in clinical trials and not approved in New Zealand or the United States.

A 23‑year‑old Palmerston North man was charged with possessing retatrutide and prescription‑only testosterone enanthate; penalties under the Medicines Act 1981 reach a $500 fine or three months’ imprisonment.

Medsafe has logged seven adverse‑reaction reports since May, about five linked to products the users believed were retatrutide. Symptoms ranged from nausea and blurred vision to liver and kidney damage. The deeper problem, regulators say, is that no one knows what the vials contain. The New Zealand Drug Foundation’s checking clinic has seen submissions jump from one sample in 2023 to 67 so far this year.

“In a handful of samples we’ve found fillers such as flour, which could cause problems if injected.”

executive director Sarah Helm told The Spinoff, adding that the service cannot test for heavy metals, bacteria, endotoxins or mould.

At least 25 local peptide websites have been shut down, The Post reported. One New Zealand‑focused site, operated by Hong Kong‑registered Global Bio Research Limited, requires buyers to be 18 and labels products “for laboratory research purposes only” while categorising them by human concerns such as anti‑ageing and weight loss.

Medsafe says the disclaimer carries no legal weight and has been contacting domestic sites to warn that sales are illegal.

Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, operates as a business unit of the Ministry of Health with approximately 60 staff split between a Wellington head office handling product approvals and standard-setting and an Auckland office running Investigation and Border Control functions. It administers the Medicines Act 1981 and Medicines Regulations 1984, the legislation under which unapproved peptide sales are being pursued.

Google search interest for “peptides” peaked in August 2026, climbing rapidly from mid‑2025 when the first weight‑loss peptides gained approval. Across the Tasman, New South Wales emergency departments recorded 1,180 peptide‑related presentations in a 15‑month span, rising from five cases in July 2025 to 217 in September 2026.